1351692-92-6

1351692-92-6 structure

Name: Febuxostat acyl glucuronide
Chemical Name: (2S,3S,4S,5R,6S)-6-[2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carbonyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
CAS Number: 1351692-92-6
Molecular Formula: C₂₂H₂₄N₂O₉S
Molecular Weight: 492.50
Catalog: Signaling Pathways Metabolic Enzyme/Protease Xanthine Oxidase
Create Date: 2017-09-01 13:40:41
Modify Date: 2026-07-03 20:03:26
Febuxostat acyl glucuronide (Febuxostat acyl-β-D-glucuronide) is a metabolite of Febuxostat (HY-14268). Febuxostat is a potent, selective and non-purine xanthine oxidase (XO) inhibitor[1].

Name	(2S,3S,4S,5R,6S)-6-[2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carbonyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
Synonyms	β-D-Glucopyranuronic acid, 1-[2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecboxylate] (2S,3S,4S,5R,6S)-6-[2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carbonyl]oxy-3,4,5-trihydroxyoxane-2-cboxylic acid Febuxostat Acyl-\|A-D-glucuronide Febuxostat-acyl-beta-D-glucuronide min 2-[3-Cyano-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecboxylate β-D-Glucopyranuronic Acid Febuxostat Acyl-β-D-glucuronide 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylate \|A-D-Glucopyranuronic Acid Febuxostat Impurity 2-(3-Cyano-4-isobutyloxyphenyl)-4-Methyl- 5-thiazolecboxylate β-D-Glucopyranuronic Acid 2-(3-Cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylate \|A-D-Glucopyranuronic Acid

Description	Febuxostat acyl glucuronide (Febuxostat acyl-β-D-glucuronide) is a metabolite of Febuxostat (HY-14268). Febuxostat is a potent, selective and non-purine xanthine oxidase (XO) inhibitor[1].
Related Catalog	Research Areas >> Metabolic Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Xanthine Oxidase
References	[1]. Bishoy Kamel, et al. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. Clin Pharmacokinet. 2017 May;56(5):459-475. [2]. Kamel B, et al. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. Clin Pharmacokinet. 2017 May;56(5):459-475.